Hamburg - On January 11, 2021, Sterna Biologicals, a German innovative clinical-stage immunology company developing novel immunomodulation therapies for patients suffering from type 2 inflammatory diseases, announced the completion of a Series A financing round totalling EUR 22.0 million (USD 23.2 million).
The proceeds from this round will fund Sterna's next phase 2 clinical trial with SB010 in moderate to severe asthma, the development of an oral formulation for SB012 for the treatment of moderate to severe ulcerative colitis, and related CMC activities.
“We are very pleased with having received such a strong vote of confidence from existing and new investors. Their financial commitment validates our highly promising GATA-3 targeting treatment approach with DNAzyme hgd40 and our comprehensive non-clinical and clinical data package with this unique and novel molecule.”, said Sterna's Chief Executive Officer Christian M. Pangratz.
NEUWERK advised Sterna Biologicals on the transaction. For more information, please see Sterna's press release.
Advisors for Sterna Biologicals: NEUWERK, Hamburg Kirsten Seeger (partner Corporate/M&A)
Daniel Meyer (Associate)
About NEUWERK: NEUWERK was founded in 2016 by lawyers from Freshfields Bruckhaus Deringer and ROXIN in Hamburg. NEUWERK brings together specialists from the fields of labor law, corporate law/M&A, IP/IT, real estate law, litigation and white-collar criminal law/criminal compliance.
Press contact: For further questions please contact Dr. Sebastian Naber (firstname.lastname@example.org), T +49 40 340 5757-30.
NEUWERK Rechtsanwälte PartG mbB, Gänsemarkt 35, 20354 Hamburg, Germany www.neuwerk.legal